26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Migraine remains poorly treated, with few effective preventive drugs available. We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention.

          Related collections

          Author and article information

          Journal
          Lancet Neurol
          The Lancet. Neurology
          1474-4465
          1474-4422
          Sep 2014
          : 13
          : 9
          Affiliations
          [1 ] Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: dodick.david@mayo.edu.
          [2 ] NIHR Wellcome Trust Clinical Research Facility, Kings College London, London, UK; Department of Neurology, University of California, San Francisco CA, USA.
          [3 ] Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Craniofacial Pain Center, Tufts University School of Dental Medicine, Boston, MA, USA; Headache and Face Pain Program, Tufts Medical Center, Boston, MA, USA.
          [4 ] Eli Lilly and Company, Indianapolis, IN, USA.
          [5 ] Arteaus Therapeutics, Cambridge, MA, USA.
          Article
          S1474-4422(14)70128-0
          10.1016/S1474-4422(14)70128-0
          25127173
          8bd04c92-5fbb-4b60-901a-0bd809859619
          Copyright © 2014 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article